New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials4.
- Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials4.
- The US Food and Drug Administration (FDA) recently approved the expanded use of Xolair in children and adults with IgE-mediated food allergies based on the OUtMATCH data.
- "While allergic reactions to exposures are common and often severe, there have been limited treatment advancements for food allergy.
- The results of the OUtMATCH study showed that anti-IgE therapy could significantly reduce the occurrence of allergic reactions across multiple foods in the event of an accidental exposure."